Auxogyn Inc. believes it has found a way to increase the success rate of in vitro fertilization procedures. Its new, noninvasive imaging technology is designed to provide novel data regarding the viability of an embryo, and using time-lapse imaging, will allow embryologists to determine which embryos have the highest likelihood of developing into blastocytes and result in a health pregnancy.
Increasing the odds in IVF
1490 O'Brien Drive
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
The Italian drugmaker gets rights to Phase III-ready asset radiprodil.
GlycoEra unveiled a $130m series B financing, saying the proceeds would enable it to take its first clinical candidate through proof-of-concept in autoimmune diseases.
New CEO Renée Aguiar-Lucander is marking her mark.
